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- 14.2] for arm A, 9.2 m [7.4 - 10.5] for arm B. TTP was 5.4 m in arm 
A and 5.7 in arm B. There were 1 grade III/IV haematological toxicities 
in arm A (1.2%) and 2 in arm B (2.4%). There were 4 grade III/IV non 
haematological toxicities in arm A (4.8%) and 6 in arm B (7.3%). 
Conclusion: The switch between the two regimen is feasible without 
any major toxicities. Despite higher response rate in favour of the 
switch strategy, OS and TTP are similar between the two arms. A new 
censor date is ﬁxed at 1st June 2007. Overall survival and TTP will be 
updated for a ﬁnal analysis.
SD n = 87 PD (%) SD (%) OR (%) NA (%)
Arm A (n = 45) 24.4 53.3 15.6 6.6
Arm B (n = 42) 11.9 59.5 21.4 7.1
95% CI ORR ; Arm A: 15.6 [6.49 - 29.45] ;  Arm B: 21.4 [10.3 - 36.81]
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Background: Imatinib inhibits activated PDGF-Rβ and down-regu-
lates VEGF resulting in decreased angiogenesis and improved blood 
ﬂow favoring enhanced tumor drug delivery. 
Objectives: 1) determine the MTD for the combination of imatinib and 
cisplatin plus docetaxel in NSCLC pts, 2) describe non-dose limiting 
toxicities (non-DLT), 3) evaluate for feasibility and changes tumor 
angiogenesis measurement by DCE-MRI after treatment with imatinib. 
DCE-MRI detects speciﬁc properties of vascular beds by virtue of the 
differential distribution of contrast media in normal and pathological 
regions. 
Methods: Eligibility: NSCLC with tumor expression of p-PDGF-Rβ. 
DCE-MRI was performed before and after 7 daily doses of imatinib 
alone (lead-in) followed by cisplatin plus docetexel on day 1, every 
3 weeks. Once daily imatinib was given with each cisplatin plus 
docetaxel cycle, on days -5 to +2. Standardized hemodynamic param-
eters (Ktrans, Ve, Kep) were acquired from DCE-MRI. 
Results: 14 enrolled pts (9 M, 5 F) were evaluable for toxicity and 13 
for response. Six pts were treated at dose level 1 (C+D 60/60 mg/m2, 
and I 300 mg); one DLT (febrile neutropenia) was seen; there were 
no DLTs in cohort 2 (60/60 mg/m2 and I 400mg; n=3), and two DLTs 
were observed in cohort 3 (70/70 mg/m≥ and I 400mg; n=5) - febrile 
neutropenia and grade 4 diarrhea. For all cohorts, grade 3 and 4 toxici-
ties were: fatigue (7%), nausea (14%), neutropenia (14%), elevated 
creatinine (7%), and dispnea (7%). Two pts (15%) had partial response, 
and 6/13 pts had stable disease as their best response. DCE-MRI dem-
onstrated trend in decrease of Ve after 7-day treatment with imatinib 
(p=0.088). 
Conclusion: MTD for imatinib and cisplatin plus docetaxel in chemo 
naïve NSCLC pts is 400 mg and 60/60 mg/m≥, respectively. More, 
DCE-MRI is feasible in NSCLC pts. DCE-MRI measured reduction 
in tumor extracellular extravascular space (Ve) suggests decrease in 
intra-tumoral pressure after PDGF-Rβ inhibition, which could mean 
improvement in tumor drug delivery. Further studies exploring DCE-
MRI as an imaging biomarker-predictor to antiangiogenic therapy in 
patients with NSCLC are ongoing.
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irradiated and pretreated patients with metastatic non-small-cell 
lung cancer
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Background: Brain metastases are a common feature of non-small-
cell lung cancer (NSCLC) and are gaining more and more attention, 
as combined modality treatment and efﬁcient new drug therapies have 
improved local control and overall survival rates. The clinical man-
agement of brain metastases is of critical importance to prevent rapid 
disease deterioration and symptom-driven worsening of quality of 
life. Therapeutic options for cranial progression after previous whole 
brain irradiation and chemotherapy-induced tumor remission are very 
limited. No established therapeutic approaches exist for cranial relapse 
after response to previous radiotherapy and systemic chemotherapy. 
Casuistry reporting of experiences with new agents in such patients 
may help to build up a rationale for new therapy sequences in this hard-
to-treat patient population.
Methods: Presented are two case reports arising from our hospitals’ 
two-years lasting clinical experience with erlotinib, a TK-EGFR-in-
hibitor approved to treat patients with locally advanced or metastatic 
NSCLC after failure of at least one prior chemotherapy regimen. Erlo-
tinib was used in accordance with prescribing information as third-line 
therapy in two non-smoking women, one with adenocarcinoma and the 
other one with bronchioloalveolar carcinoma histology. Both patients 
were initially staged M+ due to distant lymph node and contra-lateral 
pulmonary tumor manifestation.
Results: After occurrence of brain metastases in autumn 2004, both 
patients underwent standard whole brain irradiation with 40 Gy. The 
well-tolerated radiotherapy was followed by second-line chemotherapy 
which resulted in both cases into a consolidation of the thoracic and 
cranial tumor manifestation for around six months. Pulmonary and 
cerebral progression requested in both cases for a therapeutic alter-
native. Tyrosine kinase (TK) inhibition began in July respectively 
October 2005. In the ﬁrst patient, therapy was stopped despite ongoing 
cranial and pulmonary remission after 9 months due to the appear-
ance of hepatic metastasis. In the second patient, erlotinib therapy was 
continued for 15 months with a lasting cranial (CR) and thoracic (PR) 
remission. Surgery (partial laminectomy of axis and atlas) plus post-op-
erative cranial-cervical irradiation (40 Gy) were adequate measures to 
control beginning osseous metastasis in September 2006. After signs of 
pulmonary recurrence, therapy was stopped in December 2006. In both 
patients, the therapy was well tolerated with minimal side effects and 
improved quality of life scores. With view to the generally poor prog-
nosis of metastatic brain cancer with its median survival of 3-4 months, 
the sustained objective remission and control of cranial metastases for 
about 9 respectively more than 15 months is noteworthy.
Conclusions: The ability of TK-inhibitors as erlotinib to induce objec-
tive remissions in brain metastases which occurred after initial whole 
brain irradiation and which relapsed after previous chemotherapy, 
requires attention. The observed total survival times of above 18 
